
    
      Despite cytoreductive surgery and platinum-based chemotherapy, about 70% of patients with
      advanced ovarian cancer recur in the first 2 - 3 years. PARPi has been shown to be prolong
      survival in primary advanced ovarian cancer. However its role in neoadjuvant setting has not
      been fully evaluated.
    
  